NCT03411330View on ClinicalTrials.gov

Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

April 22, 2018

Study Completion Date

April 24, 2018

Conditions
Addition of Hyalase to Local Anesthetic in Scalp Block
Interventions
DRUG

Hyaluronidase

Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml

DRUG

Lidocaine

lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)

DRUG

Bupivacaine

bupivacaine (0.5%)

Trial Locations (1)

11451

Ahmed Abdalla Mohamed, Cairo

All Listed Sponsors
collaborator

Mohamed, Ahmed A., M.D.

INDIV

collaborator

Tarek Ahmed Radwan

UNKNOWN

collaborator

Mohamed Mahmoud Mohamed

UNKNOWN

collaborator

Hatem Abdellatif Mohamed

UNKNOWN

collaborator

Badawy Mohammed Al-Kholy

UNKNOWN

lead

Cairo University

OTHER

NCT03411330 - Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study | Biotech Hunter | Biotech Hunter